SpIDnet: Invasive pneumococcal disease in European Union and European Economic Area

Project description

The SpIDnet (Streptococcus pneumoniae Invasive Disease network) aimed to strengthen
surveillance for invasive pneumococcal disease (IPD) in all age groups. SpIDnet includes
multicentre studies to measure the effectiveness (VE) of pneumococcal vaccines and impact of vaccination programmes in Europe.

Context situation

Streptococcus pneumoniae infection constitutes a major public health problem worldwide, with almost 100 serotypes identified so far. Invasive pneumococcal disease (IPD) incidence rates vary across countries, depending on clinical practices, organisation of health care and
surveillance systems.
Two major groups of pneumococcal vaccines are currently available: polysaccharide vaccines, i.e. 23-valent vaccine (PPV23) and conjugate vaccines (PCV). Starting in 2009, conjugate vaccines covering 10 and 13 serotypes have replaced the 7-valent vaccine in most European countries. New vaccines covering 15 and 20 serotypes will be gradually included in the vaccination programmes following authorisation in Europe.

Sponsor or customer

European Centre for Disease Prevention and Control 2012-2020 European Union’s Horizon 2020 research and innovation programme under grant agreement No634446 (H2020 I-MOVE+) 2015-2018

Dates of the project

2012-2020

Project activities

Development of protocols

Development of generic protocols for IPD surveillance, pneumococcal vaccines’ effectiveness studies (indirect cohort method, cohort) and for impact of vaccination programmes studies.

Coordination of networks

Coordination of multicentre, multicountry surveillance and research networks: review of protocols, organisation of scientific conferences and technical workshops

Pooled data analysis

Pooled analyses to provide pneumococcal vaccines’ effectiveness and population level impact estimates at the European level: data management, data validation, development of scripts, report writing, scientific communications.

Participation of global surveillance & research

Contributed to the global surveillance and research on pneumococcal diseases (PSERENADE).

Scientific publications

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries Europe

Hanquet G., Krizova P., Dalby T., Ladhani S.N., Nuorti J.P., Danis K., Mereckiene J., Knol M.J., Winje B.A., Ciruela P., de Miguel S., Portillo M.E., MacDonald L., Morfeldt E., Kozakova J., Valentiner-Branth P., Fry N.K., Rinta-Kokko H., Varon E., Corcoran M., van der Ende A., Vestrheim D.F., Munoz-Almagro C., Sanz J-C., Castilla J., Smith A., Henriques-Normark H., Colzani E., Pastore-Celentano L., Savulescu C., the SpIDnet group

Emerg. Infect. Dis. 2022;28:137–138. doi: 10.3201/eid2801.210734.

Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study

Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, Mereckiene J, Knol M, Winje BA, Ciruela P, de Miguel S, Guevara M, MacDonald L, Kozakova J, Slotved HC, Fry NK, Pekka Nuorti J, Danis K, Corcoran M, van der Ende A, Vestrheim DF, Munoz-Almagro C, Sanz JC, Castilla J, Smith A, Colzani E, Pastore Celentano L, Hanquet G; SpIDnet VE study group.

Vaccine. 2022 Jun 23;40(29):3963-3974. doi: 10.1016/j.vaccine.2022.05.011. Epub 2022 May 28. PMID: 35637067.

Available here

Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms.

Deloria Knoll M, Bennett JC, Garcia Quesada M, Kagucia EW, Peterson ME, Feikin DR, Cohen AL, Hetrich MK, Yang Y, Sinkevitch JN, Ampofo K, Aukes L, Bacci S, Bigogo G, Brandileone MC, Bruce MG, Camilli R, Castilla J, Chan G, Chanto Chacón G, Ciruela P, Cook H, Corcoran M, Dagan R, Danis K, de Miguel S, De Wals P, Desmet S, Galloway Y, Georgakopoulou T, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kellner JD, Kleynhans J, Knol MJ, Kozakova J, Kristinsson KG, Ladhani SN, Lara CS, León ME, Lepp T, Mackenzie GA, Mad'arová L, McGeer A, Mungun T, Mwenda JM, Nuorti JP, Nzoyikorera N, Oishi K, De Oliveira LH, Paragi M, Pilishvili T, Puentes R, Rafai E, Saha SK, Savrasova L, Savulescu C, Scott JA, Scott KJ, Serhan F, Setchanova LP, Sinkovec Zorko N, Skoczyńska A, Swarthout TD, Valentiner-Branth P, van der Linden M, Vestrheim DF, von Gottberg A, Yildirim I, Hayford K; The Pserenade Team

2021 Apr 2;9(4):742. doi: 10.3390/microorganisms9040742. PMID: 33918127; PMCID: PMC8066045

Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination

Hanquet G, Krizova K, Valentiner-Branth P, Ladhani SN, Nuorti JK, Lepoutre A, Mereckiene J, Knol M, Winje BA, Ciruela P, Ordobas M, Guevara M, McDonald E, Morfeldt E, Kozakova J, Slotved HC, Fry NK, Rinta-Kokko H, Varon E, Corcoran M, van der Ende A, Vestrheim DF, Munoz-Almagro C, Latasa P, Castilla J, Smith A, Henriques-Normark B, Whittaker R, Pastore Celentano L, Savulescu C, on behalf of The SpIDnet/I-MOVE+ Pneumo Group

Thorax. 2019 May;74(5):473-482. doi: 10.1136/thoraxjnl-2018-211767. Epub 2018 Oct 24

Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study

Savulescu C, Krizova P, Lepoutre A, Mereckiene J, Vestrheim DF, Ciruela P, Ordobas M, Guevara M, McDonald E, Morfeldt E, Kozakova J, Varon E, Cotter S, Winje BA, Munoz-Almagro C, Garcia L, Castilla J, Smith A, Henriques-Normark B, Celentano LP, Hanquet G; SpIDnet group

Lancet Respir Med. 2017 Mar 27. pii: S2213-2600(17)30110-8. doi: 10.1016/S2213-2600(17)30110-8

Find all our scientific publications